Literature DB >> 33586076

PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells.

Osamu Handa1, Kyousuke Goda2, Yukiko Handa2, Shinya Fukushima2, Motoyasu Osawa2, Takahisa Murao2, Hiroshi Matsumoto2, Eiji Umegaki2, Yoshihiko Fujita3, Kazuto Nishio3, Akiko Shiotani2.   

Abstract

BACKGROUND: Esophageal cancer is a lethal malignancy with a poor prognosis. The incidence of esophageal adenocarcinoma, which develops from Barrett's esophagus (BE), has recently been increasing. In a previous study, we found that PDZK1 expression is higher in long segment BE compared to that in short-segment BE. However, the function of PDZK1 in the mucosa of BE is unclear. AIMS: Clarify the role of PDZK1 in BE mucosa using PDZK1 overexpressed cells.
METHODS: Human adenocarcinoma-derived OE33 cells were used as a parental cell line and transfected to generate PDZK1 overexpressed OE33 cells (PC cells) or transfected with empty vector as control cells (NC cells). Cell growth of NC and PC cells in 10% fetal bovine serum was evaluated by cell counting. The effect of PDZK1 on proteasome inhibitor (PSI)-induced apoptosis was qualified by fluorescence microscopy and quantified by flow cytometry. Expression of apoptosis-related proteins was evaluated by western blotting.
RESULTS: There were no significant differences in cell growth between NC and PC cells. PSI significantly increased apoptosis in NC cells, but not in PC cells. In response to PSI, increased levels of cleaved-caspase3 and decreased pro-caspase3 levels were found in NC cells, but not in PC cells. In NC cells, PSI significantly decreased Bcl-2 expression without affecting Bax levels. In contrast, high expression of both Bcl-2 and Bax was observed in PC cells.
CONCLUSION: Overexpression of PDZK1 protein induces an apoptosis-resistant phenotype in BE cells, which may be a potential therapeutic target.

Entities:  

Keywords:  Apoptosis; Barrett’s esophagus; Esophageal adenocarcinoma; PDZK1

Mesh:

Substances:

Year:  2021        PMID: 33586076     DOI: 10.1007/s10388-021-00819-z

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  31 in total

1.  Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains.

Authors:  O Kocher; N Comella; K Tognazzi; L F Brown
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

2.  Is the incidence of esophageal adenocarcinoma increasing in Japan? Trends from the data of a hospital-based registration system in Akita Prefecture, Japan.

Authors:  Shigeto Koizumi; Satoru Motoyama; Katsunori Iijima
Journal:  J Gastroenterol       Date:  2017-11-14       Impact factor: 7.527

3.  Global trends in esophageal cancer.

Authors:  Gautam K Malhotra; Ujwal Yanala; Advaitaa Ravipati; Matthew Follet; M Vijayakumar; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2017-03-20       Impact factor: 3.454

Review 4.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Thomas M Runge; Julian A Abrams; Nicholas J Shaheen
Journal:  Gastroenterol Clin North Am       Date:  2015-04-09       Impact factor: 3.806

5.  Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.

Authors:  Heiko Pohl; Oliver Pech; Haris Arash; Manfred Stolte; Hendrik Manner; Andrea May; Klaus Kraywinkel; Amnon Sonnenberg; Christian Ell
Journal:  Gut       Date:  2015-06-25       Impact factor: 23.059

Review 6.  Recent developments in esophageal adenocarcinoma.

Authors:  Jesper Lagergren; Pernilla Lagergren
Journal:  CA Cancer J Clin       Date:  2013 Jul-Aug       Impact factor: 508.702

7.  Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy.

Authors:  Kyosuke Goda; Takahisa Murao; Yukiko Handa; Ryo Katsumata; Shinya Fukushima; Rui Nakato; Motoyasu Osawa; Manabu Ishii; Minoru Fujita; Osamu Handa; Hiroshi Matsumoto; Yoshihiko Fujita; Kazuto Nishio; Timothy M Wallace; Rene Gomez-Esquivel; Manuel Berzosa; Herbert C Wolfsen; Michael B Wallace; Eiji Umegaki; Akiko Shiotani
Journal:  Esophagus       Date:  2020-07-29       Impact factor: 4.230

8.  EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.

Authors:  Wenfang Yao; Duiping Feng; Weihua Bian; Longyan Yang; Yang Li; Zhiyu Yang; Ying Xiong; Junfang Zheng; Renyou Zhai; Junqi He
Journal:  Amino Acids       Date:  2012-04-04       Impact factor: 3.520

9.  Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.

Authors:  Junfang Zheng; Lei Wang; Zhiqiang Peng; Ying Yang; Duiping Feng; Junqi He
Journal:  EBioMedicine       Date:  2016-12-09       Impact factor: 8.143

10.  Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries.

Authors:  Martin C S Wong; Willie Hamilton; David C Whiteman; Johnny Y Jiang; Youlin Qiao; Franklin D H Fung; Harry H X Wang; Philip W Y Chiu; Enders K W Ng; Justin C Y Wu; Jun Yu; Francis K L Chan; Joseph J Y Sung
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

View more
  1 in total

1.  A Genome-Wide Investigation of Effects of Aberrant DNA Methylation on the Usage of Alternative Promoters in Hepatocellular Carcinoma.

Authors:  Yuting Dong; Xiaozhao Liu; Bijun Jiang; Siting Wei; Bangde Xiang; Ruichu Liao; Qiuyan Wang; Ximiao He
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.